ASP email

ASP Participant Survey: text for email messages and survey introduction

Email invitation

Dear NINDS Anticonvulsant Screening Program participant,

NINDS is conducting a survey of individuals who have submitted compounds for screening in the Anticonvulsant Screening Program over the past five years to assess your satisfaction with services and consultation received, to determine the extent to which the program has benefitted your or your organization’s epilepsy drug development efforts, and to obtain feedback relevant to program improvement. We would be grateful for your candid responses to the questions in this survey, which you can access online or via smartphone using the links below. Please note that these links are intended only for past ASP participants invited to complete this survey and should not be shared. The survey will remain open from Nov X-YY, 2014.

(insert links here)

The survey will take approximately 15 minutes to complete. Your participation is voluntary, and you may stop the survey at any time without penalty or skip questions you do not wish to answer. Please note that your responses will not be identified with you personally or with your organization; survey results will be reported only in aggregate or de-identified form. NINDS does not plan to publish results of this survey but will use the responses received to inform future program directions to address current needs and opportunities in epilepsy drug development research.

Thank you in advance for sharing your thoughts and experiences with us. If you have any technical difficulty accessing or responding to the survey, please contact Dr. Cara Long (cara.long@nih.gov).

Reminder email invitation (send 1.5 weeks before the survey closes)

Dear NINDS Anticonvulsant Screening Program participant,

If you have not already responded, please be reminded that NINDS is conducting a survey of individuals who have submitted compounds for screening in the Anticonvulsant Screening Program over the past five years to assess your satisfaction with services and consultation received, to determine the extent to which the program has benefitted your or your organization’s epilepsy drug development efforts, and to obtain feedback relevant to program improvement. We would be grateful for your candid responses to the questions in this survey, which you can access online or via smartphone using the links below. Please note that these links are intended only for past ASP participants invited to complete this survey and should not be shared. The survey will close at XX time on Nov XX.

(insert links here)

The survey will take approximately 15 minutes to complete. Your participation is voluntary, and you may stop the survey at any time without penalty or skip questions you do not wish to answer. Please note that your responses will not be identified with you personally or with your organization; survey results will be reported only in aggregate or de-identified form. NINDS does not plan to publish results of this survey but will use the responses received to inform future program directions to address current needs and opportunities in epilepsy drug development research.

Thank you in advance for sharing your thoughts and experiences with us. If you have any technical difficulty accessing or responding to the survey, please contact Dr. Cara Long (cara.long@nih.gov).

Text to appear at the top of the survey:

OMB Control # 0925-0678,

Exp. August 2016

Public reporting burden for this collection of information is estimated to average 15 minutes, including the time for reviewing instructions, searching or gathering data needed, and completing and reviewing responses to be provided. A U.S. government agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA 0925-0678. Do not return the completed survey to this address.

Thank you for providing feedback on your experiences with the NINDS Anticonvulsant Screening Program (ASP).

The ASP was established to encourage and facilitate the discovery of new therapeutic agents for epilepsy. NINDS is conducting this survey of participants who have submitted compounds for screening in the ASP over the past five years to assess satisfaction with services and consultation received, to determine the extent to which participants feel the program has benefitted their epilepsy drug development efforts, and to obtain feedback relevant to program improvement.

Your participation in this survey is voluntary, and you may stop the survey at any time without penalty or skip questions you do not wish to answer. Please note that your responses will not be identified with you personally or with your organization; survey results will be reported only in aggregate or de-identified form. NINDS does not plan to publish results of this survey but will use the responses received to inform future program directions to address current needs and opportunities in epilepsy drug development research.

If you have questions about the survey, or if you have any technical difficulty accessing or responding to the survey, please contact Dr. Cara Long (cara.long@nih.gov).